Chi-Med Files For Hong Kong Listing That Could Raise $500m

Chi-Med has applied to list in Hong Kong and will undertake a new global share offering as it looks to raise new funds to support the progress and commercialization of its growing pipeline. 

Hong Kong
Chi-Med To List In Its Home Hong Kong • Source: Shutterstock

Hutchison China MediTech Ltd. (Chi-Med) has filed an application for a new share listing on The Stock Exchange of Hong Kong (SEHK), to raise new financing designed mainly to move forward and take to market its growing oncology-focused pipeline.

While pricing has not been set and Chi-Med did not give any target, reports suggest that the listing – expected...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

More from Scrip

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.